Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.
about
Small airway dysfunction and bronchial asthma control : the state of the artThe management of asthmatic smokersAgonist binding to β-adrenergic receptors on human airway epithelial cells inhibits migration and wound repair.Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma.Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on AsManifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on AsA Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma.
P2860
Q28067594-1ED0832A-4BFF-4BB6-AF23-BA77CD833C0EQ28076057-4FD12245-EBB5-4997-ADC7-B8CBEA2763BBQ36381803-B370C29B-596E-4E9A-BD47-1DB6C8A5398EQ36970994-79B76204-1782-40A0-99AE-BB3700607D95Q37374602-699686D3-1F83-4C69-B12D-14CD40E66AEBQ37481285-AF954232-AE11-4093-AC93-DAA1E7D588B8Q37685496-F35E8075-043D-4D4A-897B-011150D58395Q38875761-6C12F66D-C40A-4EE5-ADA2-02FC8348B854Q41018618-0933584A-3462-475F-9445-54F1FB28F3AAQ55041230-29EB3BB0-A71B-465E-ADD4-1F3FF8E9C720Q55317003-F2428B56-3F6F-454B-8821-B421BE5FA851
P2860
Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impact of extrafine formulatio ...... ed outcomes in asthma and COPD
@nl
Impact of extrafine formulatio ...... d outcomes in asthma and COPD.
@ast
Impact of extrafine formulatio ...... d outcomes in asthma and COPD.
@en
type
label
Impact of extrafine formulatio ...... ed outcomes in asthma and COPD
@nl
Impact of extrafine formulatio ...... d outcomes in asthma and COPD.
@ast
Impact of extrafine formulatio ...... d outcomes in asthma and COPD.
@en
prefLabel
Impact of extrafine formulatio ...... ed outcomes in asthma and COPD
@nl
Impact of extrafine formulatio ...... d outcomes in asthma and COPD.
@ast
Impact of extrafine formulatio ...... d outcomes in asthma and COPD.
@en
P2860
P50
P921
P3181
P356
P1476
Impact of extrafine formulatio ...... d outcomes in asthma and COPD.
@en
P2093
Federico Bellini
Nicola Scichilone
P2860
P304
P3181
P356
10.2147/PROM.S55276
P407
P577
2014-11-27T00:00:00Z